# RAMP 201 (NCT04625270)

> A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04625270
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Verastem, Inc.
- Conditions: Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer
- Interventions: avutometinib (VS-6766); avutometinib (VS-6766) and defactinib
- Enrollment: 225
- Primary outcome: Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinib
- Primary outcome: Part B: To determine the efficacy of the optimal regimen identified from Part A
- Primary outcome: Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part A
- Primary outcome: Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib

## Commentary we found

- YouTube: 18
- Podcasts: 11
- X threads: 9

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ramp-201-nct04625270

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04625270", "email": "<work email>"}; the inbox owner confirms by the emailed link.